Conflict and communication: managing the multiple affordances of take-home naloxone administration events in Australia

References

• Black L, Connolly I, Getty M, Hogan C, Lennon P, Mc Cusker M, Neale J, Strang J. 2017. Poor implementation of naloxone needs to be better understood in order to save lives. Addiction. 112(5):911–912.
   PubMed Web of Science ®Google Scholar
• Cantwell K, Dietze P, Flander L. 2005. The relationship between naloxone dose and key patient variables in the treatment of non-fatal heroin overdose in the prehospital setting. Resuscitation. 65(3):315–319.
   PubMed Web of Science ®Google Scholar
• Dettmer K, Saunders B, Strang J. 2001. Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ. 322(7291):895–896.
   PubMed Web of Science ®Google Scholar
• Dietze P, Cogger S, Malandkar D, Olsen A, Lenton S. 2015. Knowledge of naloxone and take-home naloxone programs among a sample of people who inject drugs in Australia. Illicit Drugs Reporting System Drug Trends Bulletin April 2015. Sydney (Australia): National Drug and Alcohol Research Centre, UNSW.
   Google Scholar
• Dietze P, Stare M, Coffer S, Dambiar D, Olsen A, Burns L, Lenton S. 2017. Knowledge of naloxone and take-home naloxone programs among a sample of people who inject drugs in Australia: Variations across capital cities. Drug Alcohol Rev. 37:457–463. Advance online publication.
   PubMed Web of Science ®Google Scholar
• Dilkes-Frayne E. 2014. Tracing the ‘event’ of drug use: ‘Context’ and the coproduction of a night out on MDMA. Contemporary Drug Problems. 41(3):445–479.
   Google Scholar
• Duff C. 2014. Assemblages of health: Deleuze’s empiricism and the ethology of life. New York (NY): Springer.
   Google Scholar
• Dwyer R, Olsen A, Lenton S. 2018. An overview of take-home naloxone programs in Australia. Drug Alcohol Rev. 37:440–449.
   PubMed Web of Science ®Google Scholar
• Fairbairn N, Coffin P, Walley A. 2017. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. Int J Drug Pol. 46:172–179.
   PubMed Web of Science ®Google Scholar
• Faulkner-Gurstein R. 2017. The social logic of naloxone: peer administration, harm reduction, and the transformation of social policy. Soc Sci Med. 180:20–27.
   PubMed Web of Science ®Google Scholar
• Farrugia A, Fraser S, Dwyer R, Fomiatti R, Neale J, Dietze P, Strang J. 2018. Take-home naloxone and the politics of care. Accepted for publication in Sociology of Health and Illness (21 October, 2018).
   Google Scholar
• Farrugia D. 2016. Youth homelessness in late modernity. Singapore: Springer.
   Google Scholar
• Fraser S. 2013. The missing mass of morality: a new fitpack design for hepatitis C prevention in sexual partnerships. Int J Drug Policy. 24(3):212–219.
   PubMed Web of Science ®Google Scholar
• Fraser S, Moore D, editors. 2011. The drug effect: health, crime and society. Melbourne (VIC, Australia): Cambridge University Press.
   Google Scholar
• Fraser S, Treloar C, Gendera S, Rance J. 2017. Affording’ new approaches to couples who inject drugs: A novel fitpack design for hepatitis C prevention. Int J Drug Policy. 50:19–35.
   PubMed Web of Science ®Google Scholar
• Heavey SC, Chang Y-P, Vest B, Collins R, Wieczorek W, Homish G. 2018. I have it just in case’ – Naloxone access and changes in opioid use behaviours. Int J Drug Policy. 51:27–35.
   PubMed Web of Science ®Google Scholar
• Holloway K, Hills R, May T. 2018. Fatal and non-fatal overdose among opiate users in South Wales: a qualitative study of peer responses. Int J Drug Policy. 56:56–63.
   PubMed Web of Science ®Google Scholar
• Kerr D, Dietze P, Kelly A-M, Jolley D. 2008. Attitudes of Australian heroin users to peer distribution of naloxone for heroin overdose: perspectives on intranasal administration. J Urban Health. 85(3):352–360.
   PubMed Web of Science ®Google Scholar
• Lagu T, Anderson B, Stein M. 2006. Overdoses among friends: drug users are willing to administer naloxone to others. J Subst Abuse Treat. 30(2):129–133.
   PubMed Web of Science ®Google Scholar
• Lankenau S, Wagner K, Silva K, Kecojevic A, Iverson E, McNeely M, Kral A. 2013. Injection drug users trained by overdose prevention programs: responses to witnessed overdoses. J Commun Health. 38(1):133–141.
   PubMed Web of Science ®Google Scholar
• Latour B. 2002. Morality and technology: the end of the means (trans. Venn). Theory Cult Soc. 19:247–260.
   Web of Science ®Google Scholar
• Lenton S, Dietze P, Olsen A, Wiggins N, McDonald D, Fowlie C. 2015. Working together: expanding the availability of naloxone for peer administration to prevent opioid overdose deaths in the Australian Capital Territory and beyond. Drug Alcohol Rev. 34:404–411.
   PubMed Web of Science ®Google Scholar
• Madah-Amiri D, Clausen T, Lobmaier P. 2017. Rapid widespread distribution of intranasal naloxone for overdose prevention. Drug lcohol Depend. 173:17–23.
   PubMed Web of Science ®Google Scholar
• McAuley A, Munro A, Taylor A. 2018. Once I’d done it once it was like writing your name’: lived experience of take-home naloxone administration by people who inject drugs. Int J Drug Policy. 58:46–54.
   PubMed Web of Science ®Google Scholar
• McDonald R, Campbell N, Strang J. 2017. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids—conception and maturation. Drug Alcohol Depend. 178:176–187.
   PubMed Web of Science ®Google Scholar
• McLean K. 2016. “There’s nothing here”: deindustrialization as risk environment for overdose. Int J Drug Policy. 29:19–26.
   PubMed Web of Science ®Google Scholar
• Moore D. 2004. Governing street-based injecting drug users: a critique of heroin overdose prevention in Australia. Soc Sci Med. 59(7):1547–1557.
   PubMed Web of Science ®Google Scholar
• Neale J, Strang J. 2015. Naloxone—does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin/opioid overdose. Addiction. 110(10):1644–1652.
   PubMed Web of Science ®Google Scholar
• Neale J, Brown C, Campbell ANC, Jones JD, Metz VE, Strang J, Comer SD. 2018. How competent are people who use opioids at responding to overdoses? Qualitative analyses of actions and decisions taken by lay first-responders during overdose emergencies. Addiction.
   Web of Science ®Google Scholar
• Neale J, Tompkins C, McDonald R, Strang J. 2018. Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin. Drug Alcohol Depend. 189:1–7.
   PubMed Web of Science ®Google Scholar
• Nelson M, Lenton S, Dietze P, Olsen A, Agramunt S. 2016. Evaluation of the WA Peer Naloxone Project – Final Report. Perth (Australia): National Drug Research Institute, Curtin University.
   Google Scholar
• Olsen A, McDonald D, Lenton S, Dietze P. 2015. Independent evaluation of the ‘Implementing Expanded Naloxone Availability in the ACT (I-ENAACT)’ Program, 2011-2014, final report. Canberra (Australia): ACT Health. Available at: http://www.atoda.org.au/wp-content/uploads/Naloxone-Evaluation-Report-FINAL_August-2015_BI.pdf (Accessed 25/07/18).
   Google Scholar
• Paola S. 2018. Naloxone report calls for end to ‘onerous’ barriers. AJP.com.au. https://ajp.com.au/news/naloxone-report-calls-for-end-to-onerous-barriers/ [Accessed 2018 November 29].
   Google Scholar
• Sherman S, Gann D, Scott G, Carlberg S, Bigg D, Heimer R. 2008. A qualitative study of overdose responses among Chicago IDUs. Harm Reduct J. 5(1):2.
   PubMed Web of Science ®Google Scholar
• Richert T. 2015. Wasted, overdosed, or beyond saving – to act or not to act? Heroin users’ views, assessments, and responses to witnessed overdoses in Malmo, Sweden. Int J Drug Policy. 26(1):92–99.
   PubMed Web of Science ®Google Scholar
• Roxburgh A, Hall WD, Dobbins T, Gisev N, Burns L, Pearson S, Degenhardt L. 2017. Trends in heroin and pharmaceutical opioid overdose deaths in Australia. Drug Alcohol Depend. 179(1):291–298.
   PubMed Web of Science ®Google Scholar
• Roxburgh A, Burns L. 2015. Accidental drug-induced deaths due to opioids in Australia, 2011. Sydney (Australia): NDARC, UNSW.
   Google Scholar
• Seale C. 1999. The quality of qualitative research. London: Sage.
   Google Scholar
• Sondhi A, Ryan G, Day E. 2016. Stakeholder perceptions and operational barriers in the training and distribution of take-home naloxone within prisons in England. Harm Reduction J. 13(5):1–8.
   PubMed Web of Science ®Google Scholar
• Sporer K, Kral A. 2007. Prescription naloxone: a novel approach to heroin overdose prevention. Ann Emerg Med. 49(2):172–177.
   PubMed Web of Science ®Google Scholar
• Strang J, Neale J, McDonald R, Kalk N. 2018. Toxicity: exploring and expanding the concept. Addiction. 113(4):592–594.
   Google Scholar
• Vitellone, N. (2017) Social Science of the Syringe: A Sociology of Injecting Drug Use. London & New York: Routledge.
   Google Scholar
• Wagner K, Davidson P, Iverson E, Washburn R, Burke E, Kral A, McNeeley M, Bloom J, Lankenau S. 2014. I felt like a superhero’: The experience of responding to drug overdose among individual trained in overdose prevention. International Journal of Drug Policy. 25(1):157–165.
   PubMed Web of Science ®Google Scholar
• Winston I, McDonald R, Tas B, Strang J. 2015. Heroin overdose resuscitation with naloxone: Patient uses own prescribed supply to save the life of a peer. BMJ Case Rep. DOI:10.1136/bcr-2015-210391
   Google Scholar
• Worthington N, Piper T, Galea S, Rosenthal D. 2006. Opiate users’ knowledge about overdose prevention and naloxone in New York City: a focus group study. Harm Reduction J. 3(19):1–7.
   PubMedGoogle Scholar
• Wanger K, Brough L, Macmillan I, Goulding J, MacPhail I, Christenson J. 1998. Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose. Acad Emerg Med. 5(4):293–299.
   PubMed Web of Science ®Google Scholar